The microRNAs as biomarkers: What prospects?;Les microRNA comme biomarqueurs : quelles perspectives ?

Comptes Rendus - Biologies

Volumn 340, Issue 2, 2017, Pages 114-131

  Zendjabil, Mustapha ^a   Favard, Séverine ^b   Tse, Chantal ^b   Abbou, Omar ^a   Hainque, Bernard ^b  

^a EHU   (Algeria)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Biomarkers; Body fluids; Cancers; MicroRNAs

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; GENETIC MARKER; TUMOR MARKER;

BIOASSAY; BIOMARKER; BODY FLUID; CANCER; GENOME; LITERATURE REVIEW; PHYSIOLOGY; RNA; STANDARDIZATION;

BODY FLUID; CELL VACUOLE; SHORT SURVEY; CHEMISTRY; GENETIC MARKER; GENETICS; HUMAN;

BIOMARKERS; BIOMARKERS, TUMOR; BODY FLUIDS; GENETIC MARKERS; HUMANS; MICRORNAS;

EID: 85013278054     PISSN: 16310691     EISSN: 17683238     Source Type: Journal    
DOI: 10.1016/j.crvi.2016.12.001     Document Type: Short Survey

References (123)

1. [1] McGuire, A., Brown, J.A., Kerin, M.J., Metastatic breast cancer: the potential of miRNA for diagnosis and treatment monitoring. Cancer Metastasis Rev. 4 (2015), 145–155.
2. [2] Du, T., Zamore, P.D., MicroPrimer: the biogenesis and function of microRNA. Development 132 (2005), 4645–4652.
3. [3] Lee, R.C., Feinbaum, R.L., Ambros, V., The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75 (1993), 843–854.
4. [4] Reinhart, B.J., Slack, F.J., Basson, M., Pasquinelli, A.E., Bettinger, J.C., Rougvie, A.E., et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 403 (2000), 901–906.
5. [5] Calin, G.A., Dumitru, C.D., Shimizu, M., Bichi, R., Zupo, S., Noch, E., et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. U S A 99 (2002), 15524–15529.
6. [6] Lindow, M., Kauppinen, S., Discovering the first microRNA-targeted drug. J. Cell Biol. 199 (2012), 407–412.
7. [7] Kim, V.N., Han, J., Siomi, M.C., Biogenesis of small RNAs in animals. Nat. Rev. Mol. Cell Biol. 10 (2009), 126–139.
8. [8] Siomi, M.C., Sato, K., Pezic, D., Aravin, A.A., PIWI-interacting small RNAs: the vanguard of genome defence. Nat. Rev. Mol. Cell Biol. 12 (2011), 246–258.
9. [9] Kim, V.N., MicroRNA biogenesis: coordinated cropping and dicing. Nat. Rev. Mol. Cell Biol. 6 (2005), 376–385.
10. [10] Lodish, H., Berk, A., Kaiser, C.A., Krieger, M., Molecular cell biology. 7th ed., 2012, W.H. Freeman, New York (372 p).
11. [11] Krol, J., Loedige, I., Filipowicz, W., The widespread regulation of microRNA biogenesis, function and decay. Nat. Rev. Genet. 11 (2010), 597–610.
12. [12] Marzi, M.J., Ghini, F., Cerruti, B., de Pretis, S., Bonetti, P., Giacomelli, C., et al. Degradation dynamics of microRNAs revealed by a novel pulse-chase approach. Genome Res. 26 (2016), 554–565.
13. [13] Nguyen, T.T., Brenu, E.W., Staines, D.R., Marshall-Gradisnik, S.M., MicroRNAs in the intracellular space, regulation of organelle specific pathways in health and disease. MicroRNA 3 (2014), 98–107.
14. [14] Leung, A.K., The whereabouts of microRNA actions: cytoplasm and beyond. Trends Cell Biol. 25 (2015), 601–610.
15. [15] Bandiera, S., Matégot, R., Girard, M., Demongeot, J., Henrion-Caude, A., MitomiRs delineating the intracellular localization of microRNAs at mitochondria. Free Radic. Biol. Med. 64 (2013), 12–19.
16. [16] Gantier, M.P., McCoy, C.E., Rusinova, I., Saulep, D., Wang, D., Xu, D., et al. Analysis of microRNA turnover in mammalian cells following Dicer1 ablation. Nucleic Acids Res. 39 (2011), 5692–5703.
17. [17] Kawamata, T., Tomari, Y., Making RISC. Trends Biochem. Sci. 35 (2010), 368–376.
18. [18] Zhang, X., Zuo, X., Yang, B., Li, Z., Xue, Y., Zhou, Y., et al. MicroRNA directly enhances mitochondrial translation during muscle differentiation. Cell 158 (2014), 607–619.
19. [19] miRBase. What do the miRNA names/identifiers mean? (Consulté le 29/01/2016; http://www.mirbase.org/help/nomenclature.shtml).
20. [20] Bernardo, B.C., Charchar, F.J., Lin, R.C., McMullen, J.R., A microRNA guide for clinicians and basic scientists: background and experimental techniques. Heart Lung Circ. 21 (2012), 131–142.
21. [21] Deng, G., Sui, G., Noncoding RNA in oncogenesis: a new era of identifying key players. Int. J. Mol. Sci. 14 (2013), 18319–18349.
22. [22] Weber, J.A., Baxter, D.H., Zhang, S., Huang, D.Y., Huang, K.H., Lee, M.J., et al. The microRNA spectrum in 12 body fluids. Clin. Chem. 56 (2010), 1733–1741.
23. [23] Chim, S.S., Shing, T.K., Hung, E.C., Leung, T.C., Lau, T.K., Chiu, R.W., et al. Detection and characterization of placental microRNAs in maternal plasma. Clin. Chem. 54 (2008), 482–490.
24. [24] Gilad, S., Meiri, E., Yogev, Y., Benjamin, S., Lebanony, D., Yerushalmi, N., et al. Serum microRNAs are promising novel biomarkers. PLoS One, 3, 2008, e3148.
25. [25] Chen, X., Liang, H., Zhang, J., Zen, K., Zhang, C.Y., Horizontal transfer of miRNAs: Molecular mechanisms and clinical applications. Protein Cell 3 (2012), 28–37.
26. [26] Arroyo, J.D., Chevillet, J.D., Kroh, E.M., Ruf, I.K., Pritchard, C.C., Gibson, D.F., et al. Argonaute2 complexes carry a population of vesicles in human plasma. Proc. Natl. Acad. Sci. U S A 108 (2011), 5003–5008.
27. [27] Thery, C., Ostrowski, M., Segura, E., Membrane vesicles as conveyors of immune responses. Nat. Rev. Immunol. 9 (2009), 581–593.
28. [28] Villarroya-Beltri, C., Gutierrez-Vazquez, C., Sanchez-Cabo, F., Perez-Hernandez, D., Vazquez, J., Martin-Cofreces, N., et al. Sumoylated hnRNPA2B1 controls the sorting of miRNAs into exosomes through binding to specific motifs. Nat. Commun., 4, 2013, 2980.
29. [29] Valadi, H., Ekström, K., Bossios, A., Sjöstrand, M., Lee, J.J., et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 9 (2007), 654–659.
30. [30] Guay, C., Menoud, V., Rome, S., Regazzi, R., Horizontal transfer of exosomal microRNAs transduce apoptotic signals between pancreatic beta-cells. Cell Commun. Signal., 13, 2015, 1.
31. [31] Michael, A., Bajracharya, S.D., Yuen, P.S., Zhou, H., Star, R.A., Illei, G.G., et al. Exosomes from human saliva as a source of microRNA biomarkers. Oral Dis. 16 (2010), 34–38.
32. [32] Chen, X., Liang, H., Zhang, J., Zen, K., Zhang, C.Y., Secreted microRNAs: a new form of intercellular communication. Trends Cell Biol. 22 (2012), 125–132.
33. [33] Bartels, C.L., Tsongalis, G.I., MicroRNA : nouveaux biomarqueurs des pathologies tumorales. Ann. Biol. Clin. 68 (2010), 263–272.
34. [34] Pritchard, C.C., Cheng, H.H., Tewari, M., MicroRNA profiling: approaches and considerations. Nat. Rev. Genet. 13 (2012), 358–369.
35. [35] Solayman, M.H.M., Langaee, T., Patel, A., El-Wakeel, L., El-Hamamsy, M., Badary, O., Identification of suitable endogenous normalizers for qRT-PCR analysis of plasma microRNA expression in essential hypertension. Mol. Biotechnol. 58 (2016), 179–187.
36. [36] Campomenosi, P., Gini, E., Noonan, D.M., Poli, A., D'Antona, P., Dominioni, L., et al. A comparison between quantitative PCR and droplet digital PCR technologies for circulating microRNA quantification in human lung cancer. BMC Biotechnol., 16, 2016, 60.
37. [37] Li, Y., Zhang, Z., Liu, F., Vongsangnak, W., Jing, Q., Shen, B., Performance comparison and evaluation of software tools for microRNA deep-sequencing data analysis. Nucleic Acids Res. 40 (2012), 298–305.
38. [38] Hammond, S.M., An overview of microRNAs. Adv. Drug Deliv. Rev. 87 (2015), 3–14.
39. [39] Schwarzenbach, H., Nishida, N., Calin, G.A., Pantel, K., Clinical relevance of circulating cell-free microRNAs in cancer. Nature Rev. Clin. Oncol. 11 (2014), 145–156.
40. [40] Mestdagh, P., Hartmann, N., Baeriswyl, L., Andreasen, D., Bernard, N., Chen, C., et al. Evaluation of quantitative miRNA expression platforms in the microRNA quality control (miRQC) study. Nat. Methods 11 (2014), 809–815.
41. [41] Backes, C., Sedaghat-Hamedani, F., Frese, K., Hart, M., Ludwig, N., Meder, B., et al. Bias in high-throughput analysis of miRNAs and implications for biomarker studies. Anal. Chem. 88 (2016), 2088–2095.
42. [42] Wang, K., Yuan, Y., Cho, J.H., McClarty, S., Baxter, D., Galas, D.J., Comparing the MicroRNA spectrum between serum and plasma. PLoS One, 7, 2012, e41561.
43. [43] Kim, D.J., Linnstaedt, S., Palma, J., Park, J.C., Ntrivalas, E., Kwak-Kim, J.Y., et al. Plasma components affect accuracy of circulating cancer-related microRNA quantitation. J. Mol. Diagn. 14 (2012), 71–80.
44. [44] Marzi, M.J., Montani, F., Carletti, R.M., Dezi, F., Dama, E., Bonizzi, G., et al. Optimization and standardization of circulating microRNA detection for clinical application: the miR-Test Case. Clin. Chem. 62 (2016), 743–754.
45. [45] Köberle, V., Pleli, T., Schmithals, C., Alonso, E.A., Haupenthal, J., Bönig, H., et al. Differential stability of cell-free circulating microRNAs: implications for their utilization as biomarkers. PLoS One, 8, 2013, e75184.
46. [46] El-Khoury, V., Pierson, S., Kaoma, T., Bernardin, F., Berchem, G., Assessing cellular and circulating miRNA recovery: the impact of the RNA isolation method and the quantity of input material. Sci. Rep., 6, 2016, 19529.
47. [47] Moldovan, L., Batte, K.E., Trgovcich, J., Wisler, J., Marsh, C.B., Piper, M., Methodological challenges in utilizing miRNAs as circulating biomarkers. J. Cell Mol. Med. 18 (2014), 371–390.
48. [48] Kroh, E.M., Parkin, R.K., Mitchell, P.S., Tewari, M., Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods 50 (2010), 298–301.
49. [49] Chen, F., Zhang, W., Liang, Y., Huang, J., Li, K., Green, C.D., et al. Transcriptome and network changes in climbers at extreme altitudes. PLoS One, 7, 2012, e31645.
50. [50] Li, Y., Zhang, L., Liu, F., Xiang, G., Jiang, D., Pu, X., Identification of endogenous controls for analyzing serum exosomal miRNA in patients with hepatitis B or hepatocellular carcinoma. Dis. Markers, 2015, 2015, 893594.
51. [51] Schwarzenbach, H., da Silva, A.M., Calin, G., Pantel, K., Data normalization strategies for microRNA quantification. Clin. Chem. 61 (2015), 1333–1342.
52. [52] Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136 (2015), E359–E386.
53. [53] Rupaimoole, R., Ivan, C., Yang, D., Gharpure, K.M., Wu, S.Y., Pecot, C.V., et al. Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression. Oncogene 35 (2016), 4312–4320.
54. [54] Lawrie, C.H., Gal, S., Dunlop, H.M., Pushkaran, B., Liggins, A.P., Pulford, K.L., Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br. J. Haematol. 141 (2008), 672–675.
55. [55] Ono, S., Lam, S., Nagahara, M., Hoon, D.S., Circulating microRNA biomarkers as liquid biopsy for cancer patients: pros and cons of current assays. J. Clin. Med. 4 (2015), 1890–1907.
56. [56] Moyer, V.A., U.S. Preventive Services Task Force Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med 160 (2014), 330–338.
57. [57] Smith, R.A., Manassaram-Baptiste, D., Brooks, D., Cokkinides, V., Doroshenk, M., Saslow, D., et al. Cancer screening in the United States 2014: a review of current American Cancer Society guidelines and current issues in cancer screening. CA. Cancer J. Clin., 2014, 64.
58. [58] Calin, G.A., Sevignani, C., Dumitru, C.D., Hyslop, T., Noch, E., Yendamuri, S., et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl. Acad. Sci. U S A 101 (2004), 2999–3004.
59. [59] Takamizawa, J., Konishi, H., Yanagisawa, K., Tomida, S., Osada, H., Endoh, H., et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 64 (2004), 3753–3756.
60. [60] Veronesi, G., Bianchi, F., Infante, M., Alloisio, M., The challenge of small lung nodules identified in CT screening: can biomarkers assist diagnosis?. Biomark. Med. 10 (2016), 137–143.
61. [61] Sozzi, G., Boeri, M., Rossi, M., Verri, C., Suatoni, P., Bravi, F., Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study. J. Clin. Oncol. 32 (2014), 768–773.
62. [62] Montani, F., Marzi, M.J., Dezi, F., Dama, E., Carletti, R.M., Bonizzi, G., et al. miR-Test: a blood test for lung cancer early detection. J. Natl. Cancer Inst., 107, 2015, djv063.
63. [63] Barger, J.F., Nana-Sinkam, S.P., MicroRNA as tools and therapeutics in lung cancer. Respir. Med. 109 (2015), 803–812.
64. [64] Liu, X.G., Zhu, W.Y., Huang, Y.Y., Ma, L.N., Zhou, S.Q., Wang, Y.K., High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer. Med. Oncol. 29 (2012), 618–626.
65. [65] Franchina, T., Amodeo, V., Bronte, G., Savio, G., Ricciardi, G.R., Picciotto, M., et al. Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to Pemetrexed-based chemotherapy in advanced Non-Small Cell Lung Cancer. J. Cell Physiol. 229 (2014), 97–99.
66. [66] Bonci, D., Coppola, V., Patrizii, M., Addario, A., Cannistraci, A., Francescangeli, F., et al. A microRNA code for prostate cancer metastasis. Oncogene 35 (2016), 1180–1192.
67. [67] Kelly, B.D., Miller, N., Sweeney, K.J., Durkan, G.C., Rogers, E., Walsh, K., et al. A circulating microRNA signature as a biomarker for prostate cancer in a high risk group. J. Clin. Med. 4 (2015), 1369–1379.
68. [68] Bryant, R., Pawlowski, T., Catto, J.W.F., Marsden, G., Vessella, R.L., Rhees, B., et al. Changes in circulating microRNA levels associated with prostate cancer. Br. J. Cancer 106 (2012), 68–774.
69. [69] Denis, H., Van Grembergen, O., Delatte, B., Dedeurwaerder, S., Putmans, P., Calonne, E., et al. MicroRNAs regulate KDM5 histone demethylases in breast cancer cells. Mol. BioSyst. 12 (2016), 404–413.
70. [70] Han, M., Wang, F., Gu, Y., Pei, X., Guo, G., Yu, C., et al. MicroRNA-21 induces breast cancer cell invasion and migration by suppressing smad7 via EGF and TGF-β pathways. Oncol. Rep. 35 (2016), 73–80.
71. [71] Shimomura, A., Shiino, S., Kawauchi, J., Takizawa, S., Sakamoto, H., Matsuzaki, J., et al. A novel combination of serum microRNAs for detecting breast cancer in the early stage. Cancer Sci. 107 (2016), 326–334.
72. [72] Sahlberg, K.K., Bottai, G., Naume, B., Burwinkel, B., Calin, G.A., Børresen-Dale, A., et al. A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients. Clin. Cancer Res. 21 (2015), 1207–1214.
73. [73] Ferlay, J., Le cancer du pancréas dans le monde. e-Mem. Acad. Natl. Chir. 13 (2014), 012–016.
74. [74] Kojima, M., Sudo, H., Kawauchi, J., Takizawa, S., Kondou, S., Nobumasa, H., et al. MicroRNA markers for the diagnosis of pancreatic cancer. Cancer Res., 75, 2015, 3965.
75. [75] Miyamae, M., Komatsu, S., Ichikawa, D., Kawaguchi, T., Hirajima, S., Okajima, W., et al. Plasma microRNA profiles: identification of miR-744 as a novel diagnostic and prognostic biomarker in pancreatic cancer. Br. J. Cancer 133 (2015), 1467–1476.
76. [76] Xie, Z., Yin, X., Gong, B., Nie, W., Wu, B., Zhang, X., et al. Salivary microRNAs show potential as a noninvasive biomarker for detecting resectable pancreatic cancer. Cancer Prev. Res. 8 (2015), 165–173.
77. [77] Liu, R., Chen, X., Du, Y., Yao, W., Shen, L., Wang, C., et al. Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Clin. Chem. 58 (2012), 610–618.
78. [78] Forner, A., Llovet, J.M., Bruix, J., Hepatocellular carcinoma. Lancet 379 (2012), 1245–1255.
79. [79] Wang, L., Yue, Y., Wang, X., Jin, H., Function and clinical potential of microRNAs in hepatocellular carcinoma. Oncol. Lett. 10 (2015), 3345–3353.
80. [80] Wei, J.X., Lv, L.H., Wan, Y.L., Cao, Y., Li, G.L., Lin, H.M., et al. Vps4A functions as a tumor suppressor by regulating the secretion and uptake of exosomal microRNAs in human hepatoma cells. Hepatology 61 (2015), 1284–1294.
81. [81] Ghosh, A., Ghosh, A., Datta, S., Dasgupta, D., Das, S., Ray, S., et al. Hepatic miR-126 is a potential plasma biomarker for detection of hepatitis B virus infected hepatocellular carcinoma. Int. J. Cancer 138 (2016), 2732–2744.
82. [82] Lin, X.J., Chong, Y., Guo, Z.W., Xie, C., Yang, X.J., Zhang, Q., et al. A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study. Lancet Oncol. 16 (2015), 804–815.
83. [83] Pu, X.X., Huang, G.L., Guo, H.Q., Guo, C.C., Li, H., Ye, S., et al. Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. J. Gastroenterol. Hepatol. 25 (2010), 1674–1680.
84. [84] Huang, Z., Huang, D., Ni, S., Peng, Z., Sheng, W., Du, X., Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int. J. Cancer 127 (2010), 118–126.
85. [85] Ng, E.K., Chong, W.W., Lam, E.K., Shin, V.Y., Yu, J., Poon, T.C., et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 58 (2009), 1375–1381.
86. [86] Cheng, H., Zhang, L., Cogdell, D.E., Zheng, H., Schetter, A.J., Nykter, M., et al. Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One, 6, 2011, e17745.
87. [87] Kuo, T.Y., Hsi, E., Yang, I.P., Tsai, P.C., Wang, J.Y., Juo, S.H.H., Computational analysis of mRNA expression profiles identifies microRNA-29a/c as predictor of colorectal cancer early recurrence. PLoS One, 7, 2012, e31587.
88. [88] De Smaele, E., Ferretti, E., Gulino, A., MicroRNAs as biomarkers for CNS cancer and other disorders. Brain Res., 2010, 100–111.
89. [89] Tse, C., Paris, S., Looten, V., Boch, A.L., Navarro, S., Delattre, J.Y., Hainque, B., Recherche d'une signature de microRNA circulants comme outil d'aide au diagnostic des tumeurs cérébrales primitives de l'adulte. Rev. Neurol. 170 (2014), A71–A72.
90. [90] Teplyuk, N.M., Mollenhauer, B., Gabriely, G., Giese, A., Kim, E., Smolsky, M., miRNAs in cerebrospinal fluid identify GBM and metastatic brain cancers and reflect disease activity. Neuro. Oncol. 14 (2012), 689–700.
91. [91] Akers, J.C., Ramakrishnan, V., Kim, R., Phillips, S., Kaimal, V., Mao, Y., miRNA contents of cerebrospinal fluid extracellular vesicles in glioblastoma patients. J. Neurooncol. 123 (2015), 205–216.
92. [92] Ferretti, E., De Smaele, E., Po, A., Di Marcotullio, L., Tosi, E., Espinola, M.S.B., et al. MicroRNA profiling in human medulloblastoma. Int. J. Cancer 124 (2009), 568–577.
93. [93] Wang, J., Chen, J., Sen, S., MicroRNA as biomarkers and diagnostics. J. Cell Physiol. 231 (2016), 25–30.
94. [94] Jeon, T.I., Osborne, T.F., MiRNA and cholesterol homeostasis. Biochim. Biophys. Acta, 2016, 10.1016/j.bbalip.2016.01.005.
95. [95] Nazari-Jahantigh, M., Egea, V., Schober, A., Weber, C., MicroRNA-specific regulatory mechanisms in atherosclerosis. J. Mol. Cell. Cardiol. 89 (2015), 35–41.
96. [96] Corsten, M.F., Dennert, R., Jochems, S., Kuznetsova, T., Devaux, Y., Hofstra, L., et al. Circulating MicroRNA-208b and MicroRNA-499 reflect myocardial damage in cardiovascular disease. Circ. Cardiovasc. Genet. 3 (2010), 499–506.
97. [97] Devaux, Y., Vausort, M., Goretti, E., Nazarov, P.V., Azuaje, F., Gilson, G., Use of circulating microRNAs to diagnose acute myocardial infarction. Clin. Chem. 58 (2012), 559–567.
98. [98] Long, G., Wang, F., Duan, Q., Chen, F., Yang, S., Gong, W., et al. Human circulating microRNA-1 and microRNA-126 as potential novel indicators for acute myocardial infarction. Int. J. Biol. Sci., 8, 2012, 811.
99. [99] Widera, C., Gupta, S.K., Lorenzen, J.M., Bang, C., Bauersachs, J., Bethmann, K., et al. Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome. J. Mol. Cell. Cardiol. 51 (2011), 872–875.
100. [100] Li, S., Zhu, J., Zhang, W., Chen, Y., Zhang, K., Popescu, L.M., et al. Signature microRNA expression profile of essential hypertension and its novel link to human cytomegalovirus infection. Circulation 142 (2011), 175–184.
101. [101] Guariguata, L., Whiting, D.R., Hambleton, I., Beagley, J., Linnenkamp, U., Shaw, J.E., Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res. Clin. Pract. 103 (2014), 137–149.
102. [102] Zendjabil, M., Biological diagnosis of diabetes mellitus. Curr. Res. Transl. Med. 64 (2016), 49–52.
103. [103] Marchand, L., Jalabert, A., Meugnier, E., Van den Hende, K., Fabien, N., Nicolino, M., et al. miRNA-375 a sensor of glucotoxicity is altered in the serum of children with newly diagnosed type 1 diabetes. J. Diabetes Res, 2016, 10.1155/2016/1869082.
104. [104] Nielsen, L.B., Wang, C., Sørensen, K., Bang-Berthelsen, C.H., Hansen, L., Andersen, M.L., et al. Circulating levels of microRNA from children with newly diagnosed type 1 diabetes and healthy controls: evidence that miR-25 associates to residual beta-cell function and glycaemic control during disease progression. Exp. Diabetes Res., 2012, 10.1155/2012/896362.
105. [105] Osipova, J., Fischer, D.C., Dangwal, S., Volkmann, I., Widera, C., Schwarz, K., et al. Diabetes-associated microRNAs in pediatric patients with type 1 diabetes mellitus: a cross-sectional cohort study. J. Clin. Endo. Metab. 99 (2014), E1661–E1665.
106. [106] Villard, A., Marchand, L., Thivolet, C., Rome, S., Diagnostic value of cell-free circulating MicroRNAs for obesity and type 2 diabetes: a meta-analysis. J. Mol. Biomark. Diagn., 6(6), 2015 (pii: 251).
107. [107] Marchand, L., Au-delà de la génétique conventionnelle : micro-ARN et diabète. Med. Mal. Metab. 8 (2014), 324–326.
108. [108] Zhu, H., Leung, S.W., Identification of microRNA biomarkers in type 2 diabetes: a meta-analysis of controlled profiling studies. Diabetologia 58 (2015), 900–911.
109. [109] Zampetaki, A., Kiechl, S., Drozdov, I., Willeit, P., Mayr, U., Prokopi, M., et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ. Res. 107 (2010), 810–817.
110. [110] Zhao, C., Dong, J., Jiang, T., Shi, Z., Yu, B., Zhu, Y., et al. Early second-trimester serum miRNA profiling predicts gestational diabetes mellitus. PLoS One, 6, 2011, e23925.
111. [111] Müller, M., Jäkel, L., Bruinsma, I.B., Claassen, J.A., Kuiperij, H.B., et al. microRNA-29a is a candidate biomarker for Alzheimer's disease in cell-free cerebrospinal fluid. Mol. Neurobiol. 53 (2016), 2894–2899.
112. [112] Wu, H.Z., Ong, K.L., Seeher, K.N., Armstrong, J., Thalamuthu, A., Brodaty, H., et al. Circulating microRNAs as biomarkers of Alzheimer's disease: a systematic review. J. Alzheimers Dis. 49:3 (2015), 755–766.
113. [113] Otsuka, M., Kishikawa, T., Yoshikawa, T., Yamagami, M., Ohno, M., Takata, A., et al. MicroRNAs and liver disease. J. Hum. Genet., 2016, 10.1038/jhg.2016.53.
114. [114] Janssen, H.L., Reesink, H.W., Lawitz, E.J., Zeuzem, S., Rodriguez-Torres, M., Patel, K., et al. Treatment of HCV infection by targeting microRNA. N. Engl. J. Med. 368 (2013), 1685–1694.
115. [115] Zhang, Y., Jia, Y., Zheng, R., Guo, Y., Wang, Y., Guo, H., et al. Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases. Clin. Chem. 56 (2010), 1830–1838.
116. [116] Maillard, N., Delanaye, P., Mariat, C., Exploration de la fonction glomérulaire rénale : estimation du débit de filtration glomérulaire. Nephrol. Ther. 11 (2015), 54–67.
117. [117] Lopez-Giacoman, S., Madero, M., Biomarkers in chronic kidney disease, from kidney function to kidney damage. World J. Nephrol., 4, 2015, 57.
118. [118] Szeto, C.C., Ching-Ha, K.B., Ka-Bik, L., Mac-Moune, L.F., Cheung-Lung, C.P., Gang, W., et al. Micro-RNA expression in the urinary sediment of patients with chronic kidney diseases. Dis. Mark. 33 (2012), 137–144.
119. [119] Papadopoulos, T., Belliere, J., Bascands, J.L., Neau, E., Klein, J., Schanstra, J.P., miRNAs in urine: a mirror image of kidney disease?. Expert. Rev. Molec. Diagn. 15 (2015), 361–374.
120. [120] Szeto, C.C., Urine miRNA in nephrotic syndrome. Clin. Chim. Acta 436 (2014), 308–313.
121. [121] Wang, G., Kwan, B.H., Lai, F.M., Chow, K.M., Li, P.T., Szeto, C., Urinary miR-21, miR-29, and miR-93: novel biomarkers of fibrosis. Am. J. Nephrol. 36 (2012), 412–418.
122. [122] Matz, M., Fabritius, K., Lorkowski, C., Dürr, M., Gaedeke, J., Durek, P., et al. Identification of T cell-mediated vascular rejection after kidney transplantation by the combined measurement of 5 specific microRNAs in blood. Transplantation 100 (2015), 898–907.
123. [123] Kanninen, K.M., Bister, N., Koistinaho, J., Malm, T., Exosomes as new diagnostic tools in CNS diseases. Biochim. Biophys. Acta 1862 (2016), 403–410.